Assistant Professor, School for Life Sciences, Westlake University, China
Initially trained as a clinical doctor for seven years, the applicant moved to the field of proteomics in 2007 and has been since focused on proteomic methodological development and clinical applications. During his five-year training in Ruedi Aebersold laboratory, the applicant coupled the pressure cycling technology (PCT) and SWATH technology to enable efficient analysis of biopsy-level tissue samples in high-throughput, and has contributed to the large industrialized proteomics facility ProCan in Sydney. In Aug 2017, the applicant set up the Guomics Laboratory for Proteomic Big Data in the Westlake University in Hangzhou, China, and since then generated the first 10,000-clinical-proteome data set using SWATH/DIA by collaborating with dozens of clinical collaborators from multiple countries and the big data scientists. Having studied and worked in China, Singapore, Switzerland and Australia, collaborating with colleagues in the North America, the applicant is expected to not only contribute to the penetration of proteomics into the clinical medicine community and computer science community, but also serve as a bridge to promote international collaborations.
The applicant has joined HUPO since 2010, and has contributed to the tagline of HUPO: "translating the life of code". He is passionated in contributing more to the HUPO community.
Chief, National Cancer Center, Japan
I have been participating in the HUPO since its first meeting in Versailles, Paris, 2002. My research interest has been focusing on the clinical applications of proteomics. As a scientist with medical backgrounds, I extensively challenged the cancer biomarker development for personalized medicine. I value collaborations with physicians and pathologists, and trained more than 20 young doctors in my laboratory. Every year, we presented our research in the HUPO World Congress, and my students received awards of poster presentation and travel grant. They are now leaders in the medical fields in Japan. Since 2015, I started establishing patient-derived cancer models to validate the results of proteomic studies, and provided our models to the researchers upon a request. Since 2017, I am a leader of Japan Sarcoma Team in International Cancer Proteogenomics Consortium (ICPC). In ICPC, we create novel software for proteogenomics, and provide sarcoma data. HUPO has been a good place of my research activity.
HUPO includes diverse researchers with different specialty and culture backgrounds. I have been impressed with a wide variety of presentations at the HUPO Annual Congress. However, I believe that we share one common goal, that is, the contribution to our society through proteomics. Because proteome is a central component of life, proteomics is such a powerful approach, and our research will finally lead innovative discovery, and benefit many people in the future.
If elected to the council member, I would advocate for promoting translational cancer research. Clinical questions at the bedside are valuable resources of research ideas, and cutting edge proteomics technologies potentially revolutionize clinical practice. I would also advocate for sharing valuable research resource such as cancer models. Adequate cancer models are essentially important for proteomics researchers, but not always available. I believe that my experience will be helpful in moving these works forward.
Distinguished Professor, Macquarie University and Griffith University, Australia
Having been there when the word proteomics was coined by Marc Wilkins in Sydney some 25 years ago; being one of the founding members of Proteome Systems Ltd, one of the first biotech companies in the field; and as the current Chair of the Advisory Committee of the Australian Proteome Analysis Facility (APAF), I feel that I can usefully contribute to the continuing evolution of the science in HUPO, and be part of the future development of proteomics science and its impact on our understanding of health and disease.
My expertise and interest are in the analysis of the glycosylation of proteins, and increasingly in understanding how these structures, that are a result of a complex synthetic process that produces huge variation in the properties of proteins, affect such a diverse range of cellular processes.The macro- and micro-heterogeneity of glycosyIation on the protein is responsible for the orders of magnitude increase in the number of proteoforms coded by the genome. These proteoforms perform the fine-tuning of cellular function by diverse and largely unknown mechanisms.
It has become very clear to me that not only do we need to know the genome and to identify its translated proteome, but that we must also explore the detail of the extensively modified peptides that are not used routinely in the classic protein identification workflows, and determine the effect of these modifications on protein and pathway functions. Only then will we know the true complexity of cells.
Principal Research Fellow and Professor, Monash University, Australia
My doctoral training was in protein and peptide separation and the sensitive detection and characterization of peptides. In 1994, as a postdoc I began a fascination with immune recognition and the key role peptides play in modulating health and disease. After further postdoctoral studies I was awarded a CR Roper Fellowship in 2003 and began an independent research career in which I have applied cutting edge mass spectrometry to key questions in immunology. In 2005 I moved to the Bio21 Institute as the Grimwade Research Fellow at University of Melbourne. In 2008 I was awarded an NHMRC Senior Research Fellowship and in 2009 appointed as a Reader. In July 2012 I was recruited back to Monash as a Professor and Head of Quantitative Proteomics.
I am currently Deputy Head of the Department of Biochemistry at Monash University and an executive committee member of the Australasian Proteomics Society and the Australasian Peptide Society. I am passionate about career development and mentoring early career researchers - especially in proteomics which is often complicated by the requirement for access to high end instrumentation and thus limited opportunities for early career researchers. I have been active in HUPO since 2010 regularly attending meetings and contributing to initiatives including the Human Immunopeptidome Project.
My laboratory focuses on how the diverse array of peptides presented to the immune system, the immunopeptidome, is influenced by infection, inflammation and the environment. We have made important contributions to understanding the role of antigen presentation, including characterizing peptide epitopes involved in T cell recognition in autoimmunity, allergy, cancer and infectious diseases. I have been instrumental in bringing quantitative tools to immunological studies, in particular the use of multiple reaction monitoring to calculate epitope cell surface expression. My lab was one of the first to adopt new data independent acquisition techniques and apply it to quantitate antigen presentation at the protein and peptide epitope level as well as to understand complex host-pathogen interactions.
Professor, Indian Institute of Technology Bombay, India
Dr. Srivastava is an active contributor to global proteomics science and innovation. As a Canadian trained in proteomics at the Alberta and Harvard University, he returned to India in 2009 as Assistant Professor and currently working as Professor. He has established state-of-the art proteomics facility in India. He is convener of Cancer Moonshot India project and leading ICPC project in India. He has published over 100 high impact publications and 5 special issues as editor. He has conducted 3 international conferences and several highly successful hands-on workshops. One of his special contributions has been the development of Virtual Proteomics Laboratory. He has offered massive online open courses in Proteomics and Interactomics.
He serves on the Executive Committee of Proteomics Society, India & member of US-HUPO and HUPO. He contributes actively to the HUPO-B/D Executive committee, Cancer-HPP project and Website and Social Media Committee. In HUPO conferences, he has participated as invited speaker, session chair and judge.
In an effort to enhance proteomics education & awareness among the community, he has made proteomics documentaries:
Taken together, his series of research and teaching initiatives are contributing to and fully synchronized with the mission and current activities of HUPO. He continues to develop proteomics science and innovation together with and for the next generation of keen students, researchers and the research and education commons in global HUPO community.